ID

17190

Descripción

Lingzhi and Sen Miao San for the Treatment of Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT00432484

Link

https://clinicaltrials.gov/show/NCT00432484

Palabras clave

  1. 30/8/16 30/8/16 -
Subido en

30 de agosto de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Rheumatoid Arthritis NCT00432484

Eligibility Rheumatoid Arthritis NCT00432484

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
fulfilled the 1987 american college of rheumatology (acr) criteria for ra.
Descripción

Rheumatoid Arthritis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0003873
the presence of 2 or more swollen or tender joints, based on 28-joint count.
Descripción

swollen/tender joint count

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0451521
UMLS CUI [2]
C0451530
morning stiffness lasting for 30 minutes.
Descripción

morning stiffness

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0457086
erythrocyte sedimentation rate (esr) of 28 mm/hour, despite treatment with disease modifying agent including mtx, sulphasalazine, hydroxychloroquine, auranofin or azathioprine were recruited into the study.
Descripción

erythrocyte sedimentation rate (esr), treatment with disease modifying agent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1176468
UMLS CUI [2]
C0242708
patients taking glucocorticoids (prednisone < 7.5 mg/day) and/or nonsteroidal antiinflammatory drugs must have been taking a stable dosage for at least 4 weeks before entering the trial and were required to take the same dosage throughout the trial.
Descripción

glucocorticoids and/or nonsteroidal antiinflammatory drugs, stable dosage

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0017710
UMLS CUI [1,2]
C0205360
UMLS CUI [2,1]
C0003211
UMLS CUI [2,2]
C0205360
patients had radiographic erosive diseases.
Descripción

Bone erosion

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0587240
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who are pregnant or nursing mothers.
Descripción

pregnant or breast feeding

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0006147
severe liver disease (e.g cirrhosis, chronic active hepatitis)
Descripción

Severe liver disease

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0023895
UMLS CUI [1,2]
C0205082
renal impairment (serum creatinine level > 150mmol/l)
Descripción

serum creatinine

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201976
known hypersensitivity to herbal medicine
Descripción

Hypersensitivity to herbal medicine

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0025125

Similar models

Eligibility Rheumatoid Arthritis NCT00432484

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Rheumatoid Arthritis
Item
fulfilled the 1987 american college of rheumatology (acr) criteria for ra.
boolean
C0003873 (UMLS CUI [1])
swollen/tender joint count
Item
the presence of 2 or more swollen or tender joints, based on 28-joint count.
boolean
C0451521 (UMLS CUI [1])
C0451530 (UMLS CUI [2])
morning stiffness
Item
morning stiffness lasting for 30 minutes.
boolean
C0457086 (UMLS CUI [1])
erythrocyte sedimentation rate (esr), treatment with disease modifying agent
Item
erythrocyte sedimentation rate (esr) of 28 mm/hour, despite treatment with disease modifying agent including mtx, sulphasalazine, hydroxychloroquine, auranofin or azathioprine were recruited into the study.
boolean
C1176468 (UMLS CUI [1])
C0242708 (UMLS CUI [2])
glucocorticoids and/or nonsteroidal antiinflammatory drugs, stable dosage
Item
patients taking glucocorticoids (prednisone < 7.5 mg/day) and/or nonsteroidal antiinflammatory drugs must have been taking a stable dosage for at least 4 weeks before entering the trial and were required to take the same dosage throughout the trial.
boolean
C0017710 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C0003211 (UMLS CUI [2,1])
C0205360 (UMLS CUI [2,2])
Bone erosion
Item
patients had radiographic erosive diseases.
boolean
C0587240 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
pregnant or breast feeding
Item
patients who are pregnant or nursing mothers.
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
Severe liver disease
Item
severe liver disease (e.g cirrhosis, chronic active hepatitis)
boolean
C0023895 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
serum creatinine
Item
renal impairment (serum creatinine level > 150mmol/l)
boolean
C0201976 (UMLS CUI [1])
Hypersensitivity to herbal medicine
Item
known hypersensitivity to herbal medicine
boolean
C0020517 (UMLS CUI [1,1])
C0025125 (UMLS CUI [1,2])

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial